Prospective study shows safe transition to subcutaneous infliximab in inflammatory bowel disease patients, suggesting tailored dosing based on therapy history.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bergsmark et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: